<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">Indian Journal of Ophthalmology</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18711266</article-id><article-id pub-id-type="pmc">2636134</article-id><article-id pub-id-type="publisher-id">IndianJOphthalmol_2008_56_5_385_42414</article-id><article-categories><subj-group subj-group-type="heading"><subject>Symposium</subject></subj-group></article-categories><title-group><article-title>Medical management of human immunodeficiency virus infection</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kempen</surname><given-names>John H</given-names></name></contrib></contrib-group><aff>Department of Ophthalmology, the Department of Biostatisticsand Epidemiology and the Center for Clinical Epidemiologyand Biostatistics, the University of Pennsylvania, Philadelphia,Pennsylvania, USA</aff><author-notes><corresp id="cor1">Correspondence to Dr. John H. Kempen, Center for PreventiveOphthalmology and Biostatistics, Department of Ophthalmology,University of Pennsylvania, 3535 Market Street, Suite 700, Philadelphia,PA 19104 USA. Email: <email>john.kempen@uphs.upenn.edu</email></corresp></author-notes><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2008</year></pub-date><volume>56</volume><issue>5</issue><fpage>385</fpage><lpage>390</lpage><history><date date-type="received"><day>04</day><month>6</month><year>2007</year></date><date date-type="accepted"><day>14</day><month>11</month><year>2007</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Ophthalmology</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-ShareAlike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the originalwork is properly cited.</license-p></license></permissions><abstract><p>The human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome (AIDS) pandemic haspervasive effects on culture, economics, policy, and human development. All organs can be affected bycomplications of HIV/AIDS, including the eye. When sufficient resources are available and widespreadantiretroviral resistance does not exist, the four available classes of antiretroviral agents - nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors,and fusion inhibitors - can be combined to provide highly active antiretroviral therapy (HAART). For many(not all) patients, HAART converts an inexorably fatal disease into a chronic disease with a fairly goodprognosis. Use of HAART often induces partial immune recovery, which has predominantly beneficial effectson ocular complications of AIDS. However, HAART-induced immune recovery sometimes results in immunerecovery inflammatory syndromes, such as immune recovery uveitis. Use of HAART is the single most usefulintervention for most patients with ocular complications of AIDS. However, specific ocular therapy is alsocritical to avoid blindness in the early months before immune recovery can occur, or if HAART is unavailable.Increasing availability of HAART worldwide shows great promise to alleviate one of the world&#x02032;s greatestplagues. However, predictable secular trends in the AIDS epidemic make it likely that the number of cases ofocular complications of AIDS will increase substantially before they decrease. Ophthalmologists worldwideshould be familiar with the diagnosis and management of cytomegalovirus retinitis - the most common ocularcomplication of AIDS - and should establish partnerships with physicians who are able to provide HAART.Research is needed to determine the optimal approach for managing cytomegalovirus retinitis in resource-constrained settings.</p></abstract><kwd-group><kwd>Acquired immune deficiency syndrome</kwd><kwd>antiretroviral therapy</kwd><kwd>cytomegalovirus retinitis</kwd><kwd>highly active antiretroviral therapy</kwd><kwd>human immunodeficiency virus</kwd><kwd>immune recovery</kwd></kwd-group></article-meta></front><body><p>The acquired immune deficiency syndrome (AIDS) pandemicwas first recognized in 1981 in Los Angeles, California.<xref ref-type="bibr" rid="ref1">1</xref>Unfortunately, human immunodeficiency virus (HIV) infectionwas widespread throughout the world by the time thesesentinel events were recognized. The HIV/AIDS pandemichas quickly advanced to become one of the great plagues ofall time, now affecting between 30.6 and 36.1 million personsworldwide, including approximately 2.5 million Indians[<xref ref-type="fig" rid="F1">Figure 1</xref>].<xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref3">3</xref>More than 2.08 million persons die of HIV/AIDSper year, worldwide.<xref ref-type="bibr" rid="ref3">3</xref> The pandemic has had pervasive effectson culture, economics, and policy, and has led to &#x02033;the singlegreatest reversal in human development&#x02033; in recent times.<xref ref-type="bibr" rid="ref4">4</xref> Theaim of the present article is to provide a review of the medicalmanagement of HIV infection.</p><p>Four treatment strategies have been shown to prolong survivalof patients with HIV/AIDS: antiretroviral therapy, prophylaxisfor <italic>Pneumocystis carinii</italic>,<xref ref-type="bibr" rid="ref5">5</xref> prophylaxis for <italic>Mycobacteriumavium</italic><xref ref-type="bibr" rid="ref6">6</xref>and care by a physician experienced in the management ofHIV/AIDS.<xref ref-type="bibr" rid="ref7">7</xref> Of these, only combination antiretroviral therapy,commonly called highly active antiretroviral therapy (HAART),frequently succeeds at reversing the otherwise inexorableprogression of immunodeficiency, whereas <italic>P. carinii</italic> and<italic>M. avium</italic> prophylaxis prolong survival in a state of advancedimmunodeficiency, during which time patients unfortunatelyare at increasing risk of advanced opportunistic complicationsof AIDS such as cytomegalovirus (CMV) retinitis.<xref ref-type="bibr" rid="ref8">8</xref> The currentplan for widespread introduction of inexpensive co-trimoxazoleprophylaxis<xref ref-type="bibr" rid="ref9">9</xref> will be of great value in improving survival, but therisk of CMV retinitis is likely to increase substantially as a result,in regions where HAART does not become widely used.</p><p>Highly active antiretroviral therapy is defined as &#x02033;anantiretroviral regimen that can reasonably be expected toreduce the viral load &#x0003c;50 copies/mL in treatment-na&#x000ef;vepatients&#x02033;.<xref ref-type="bibr" rid="ref10">10</xref> A foundational advance leading to HAART wasthe recognition that combination antiretroviral therapy wouldbe needed to prevent the development of viral resistanceto antiretroviral agents. The HIV, an RNA virus, mutatesapproximately once per replication, as a result of the poorfidelity of its reverse transcriptase.<xref ref-type="bibr" rid="ref11">11</xref> This property enablesHIV to rapidly develop resistance to antiretroviral treatments,unless the treatment succeeds at arresting replication nearlycompletely.<xref ref-type="bibr" rid="ref12">12</xref> Simultaneous use of multiple agents, usuallythree or more, attacking different aspects of HIV replicationis successful because HIV would have to develop mutationssimultaneously to all agents in use in order to escape control,an improbable event. However, scrupulous adherence tosuch therapy is extremely important for patients with HIVdisease, because intermittent use of antiretroviral agents leadsto the development of resistance.<xref ref-type="bibr" rid="ref13">13</xref> Less than 95% adherenceis associated with a 3.5-fold higher risk of treatment failure.<xref ref-type="bibr" rid="ref14">14</xref></p><p>The four classes of antiretroviral agents currently availableare listed in <xref ref-type="table" rid="T1">Table 1</xref>. At present, available antiretroviral drugshave their effect by interfering with one of two HIV-encodedenzymes required for reproduction of the virus (reversetranscriptase, which transcribes HIV&#x02032;s RNA genome; or HIVprotease, which is involved in the assembly and release ofdaughter viral particles) or by inhibiting fusion of the viralparticle with the target cell.</p><p>Inhibitors of reverse transcriptase are divided into twoclasses: nucleoside (or nucleotide) reverse transcriptaseinhibitors (NRTIs), which competitively inhibit the enzyme;and non-nucleoside reverse transcriptase inhibitors (NNRTIs),which covalently inactivate the reverse transcriptase, exertinga highly potent effect. Nucleoside inhibitors were the firsteffective antiretroviral drugs to be developed, beginning withzidovudine (AZT) in 1987.<xref ref-type="bibr" rid="ref15">15</xref> When given as monotherapy, mostof these drugs reduce the HIV load in peripheral blood on theorder of 0.5 to 1.0 log<sub>10</sub> units, followed by the rapid developmentof drug resistance. The six agents in this class [<xref ref-type="table" rid="T1">Table 1</xref>] are quiteuseful as a component of antiretroviral combination therapies,and are widely used. Being older medications, some of themare less expensive than newer antiretroviral agents. Tenofoviris a nucleotide, rather than a nucleoside reverse transcriptaseinhibitor, which circumvents a common mechanism of NRTIresistance, but otherwise works in a similar fashion to itscousins.</p><p>Non-nucleoside reverse transcriptase inhibitors are morepotent than nucleoside reverse transcriptase inhibitors becausethey covalently inactivate reverse transcriptase. Their side-effect profile has made the three agents in this class amongthe most popular agents for management of HIV infection,although costs tend to limit their use worldwide. Nevertheless,they are prone to extremely rapid development of resistanceif not used in appropriate combinations with a high degree ofadherence to the medication schedule.</p><p>Protease inhibitors make up a third class of antiretroviralagents, the first class of &#x02033;highly potent&#x02033; drugs to becomeavailable, suppressing HIV load by 1.0 to 2.0 log<sub>10</sub> units whengiven as monotherapy. The HIV protease cleaves polyproteinsgenerated by HIV-encoded mRNA; its blockade renders severalessential viral enzymes inactive, resulting in production ofdefective HIV virions that are rapidly cleared.<xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref17">17</xref>Nine such agents currently exist [<xref ref-type="table" rid="T1">Table 1</xref>]. Ideally, most are given inconjunction with ritonavir, for its &#x02033;boosting&#x02033; effect, whichimproves the pharmacokinetic profile of other proteaseinhibitors without incurring the extent of side-effects associatedwith full-dose ritonavir. Combination therapy with proteaseinhibitors and thymidine analog NRTIs, a highly effectiveantiretroviral combination, unfortunately is associated withmetabolic disturbances and peripheral lipoatropy, whichappear to be less common when protease inhibitors arecombined with abacavir or tenofovir.<xref ref-type="bibr" rid="ref18">18</xref> The latter agents aremore expensive than older NRTIs.</p><p>Enfuvirtide - the first agent in a fourth class of agents,fusion inhibitors, is a 36 amino acid peptide which inhibitsthe function of gp41, potently inhibiting the HIV-cellularmembrane fusion sequence.<xref ref-type="bibr" rid="ref19">19</xref> Enfuvirtide is primarily used inwealthy countries as a salvage therapy, due to its great expenseand the requirement that it be given by injection.</p><p>The arrival of HAART has led to one of the most spectacularreversals in modern medicine, converting what is otherwisean inexorably progressive, fatal disease into a chronic diseasewith a fairly good prognosis for those who receive HAARTand benefit from it. Use of HAART results in a much reducedrisk of mortality,<xref ref-type="bibr" rid="ref20">20</xref> reduced opportunistic infection risk,<xref ref-type="bibr" rid="ref21">21</xref> and improved quality of life,<xref ref-type="bibr" rid="ref22">22</xref> often with recovery to near-normalhealth. Epidemiologically, widespread use of HAART tends toresult in increased prevalence of HIV/AIDS, because survivalimproves to a greater extent than decline in transmission ofHIV infection.</p><p>Ocular complications of AIDS and their association witha patient&#x02032;s current immune status, as given by the CD4 +  Tcell count, are summarized in <xref ref-type="table" rid="T2">Table 2</xref>. The risk of developingCMV retinitis has declined substantially among patientsreceiving HAART.<xref ref-type="bibr" rid="ref23">23</xref> Among patients already afflicted byCMV retinitis, use of HAART is associated with an 81% lowerrisk of mortality,<xref ref-type="bibr" rid="ref24">24</xref> a 46% lower risk of developing retinitis inpreviously unaffected second eyes,<xref ref-type="bibr" rid="ref25">25</xref> a 60% reduction in therisk of retinal detachment<xref ref-type="bibr" rid="ref26">26</xref> and an approximate 75% reductionin the risk of loss of visual acuity.<xref ref-type="bibr" rid="ref27">27</xref> Most patients who developimmune reconstitution characterized by a rise in the CD4+ Tcell count to a level greater than 100 to 150 cells/&#x000b5;L for four tosix months can safely stop anti-CMV therapy,<xref ref-type="bibr" rid="ref28">28</xref> with only rareexceptions.<xref ref-type="bibr" rid="ref29">29</xref> Some patients also develop immune recoveryuveitis (the first immune recovery inflammatory syndromedescribed) in which recovery of anti-CMV immunity leadsto intraocular inflammation - often a vitritis - sometimescausing vision loss.<xref ref-type="bibr" rid="ref30">30</xref></p><p>Because the overall effects of immune recovery areoverwhelmingly beneficial, use of HAART is the single mostimportant intervention for patients with ocular complicationsof AIDS. In fact, even if substantial immune recovery neveroccurs, outcomes of CMV retinitis are substantially improvedin patients receiving HAART with respect to those who nevertake HAART.<xref ref-type="bibr" rid="ref24">24</xref>-<xref ref-type="bibr" rid="ref27">27</xref> However, specific ocular therapyalso is critical, in order to avoid blindness in the early months beforeimmune recovery is complete, or if antiretroviral treatmentfails to restore immunity.</p><p>Unfortunately, most persons with HIV/AIDS worldwidehave limited access to HAART, as a result of both economic andhealth infrastructure limitations. In recent years, internationalefforts and cost reductions, largely because of generic drugsavailable from Indian pharmaceutical firms, have begunimproving access to HAART. Still, only 1-1.5% of patients inIndia receive HAART presently, and the present goal is toexpand to 6-7%.<xref ref-type="bibr" rid="ref31">31</xref> While it is encouraging to observe increasinguse of combination antitretroviral therapy worldwide, it likelywill be many years until treatment is available to the majority.</p><p>In the pre-HAART era, CMV retinitis was more than20-fold more common than any other vision-threateningocular complication of AIDS in the United States<xref ref-type="bibr" rid="ref32">32</xref> and affectedapproximately 30% of all patients with AIDS at some point intheir lifetime.<xref ref-type="bibr" rid="ref33">33</xref> Case series from India and most parts of theworld<xref ref-type="bibr" rid="ref32">32</xref>-<xref ref-type="bibr" rid="ref42">42</xref> suggest that CMV retinitis is thepreeminent ocular complication of AIDS everywhere, except possibly in sub-Saharan Africa, where patients until recently have died at a stageof AIDS earlier than when CMV retinitis would be expectedto occur,<xref ref-type="bibr" rid="ref43">43</xref> a situation which is likely to change with improvedAIDS care and infrastructure. Even if the risk of CMV retinitis isone-fourth as common worldwide as it used to be in the UnitedStates, millions of persons would be affected.</p><p>Treatment of ocular complications of AIDS is a complextopic, which I have addressed in more detail elsewhere.<xref ref-type="bibr" rid="ref44">44</xref> Ingeneral, because most ocular opportunistic pathogens cannotbe eradicated, their management, including the managementof CMV retinitis, requires lifelong suppressive therapy exceptin those fortunate few in whom HAART induces sufficientrecovery of endogenous immunity to control the pathogen.Management of CMV retinitis, the most common pathogen,is particularly difficult. Even with ongoing suppressivesystemic anti-CMV therapy, recurrences of active retinitisoccur approximately every three months,<xref ref-type="bibr" rid="ref44">44</xref> due to limitations indrug delivery after restoration of the blood-retinal barrier withhealing of retinitis<xref ref-type="bibr" rid="ref45">45</xref> and/or the development of drug resistance,which occurs in about 27.5% by nine months.<xref ref-type="bibr" rid="ref46">46</xref> The alternativeof local therapy is effective, but also has its problems, withincreased risk of second eye retinitis,<xref ref-type="bibr" rid="ref47">47</xref> systemic CMV disease<xref ref-type="bibr" rid="ref47">47</xref> and possibly mortality<xref ref-type="bibr" rid="ref24">24</xref>,<xref ref-type="bibr" rid="ref47">47</xref>-<xref ref-type="bibr" rid="ref50">50</xref> hence the overarching need in thesepatients to control the underlying HIV disease and restoreendogenous immunity.</p><p>In countries with substantial treatment resources,valganciclovir<xref ref-type="bibr" rid="ref51">51</xref> is the most popular treatment for CMVretinitis, using a dose of 900 mg twice daily for initial controlof active retinitis (&#x02033;induction&#x02033;), followed by 900 mg daily assuppressive (&#x02033;maintenance&#x02033;) therapy. Valganciclovir is the onlyoral treatment for CMV with high bioavailability, avoidingthe need for a long-term central venous catheter, with itsattendant high risk of life-threatening catheter complications<xref ref-type="bibr" rid="ref52">52</xref>and quality of life problems. Valganciclovir, the valine ester ofganciclovir, achieves blood ganciclovir levels similar to thosewith intravenous ganciclovir<xref ref-type="bibr" rid="ref53">53</xref>-<xref ref-type="bibr" rid="ref55">55</xref> and therefore canserve as a replacement for intravenous ganciclovir in most situations.Oral ganciclovir is inferior to valganciclovir because of poororal bioavailability, and is no longer marketed in the west.Intravenous foscarnet<xref ref-type="bibr" rid="ref55">55</xref>,<xref ref-type="bibr" rid="ref56">56</xref> is an alternative therapyfor CMV disease, but requires several hours per day to administer, hassignificant side-effects, and is comparably expensive, makingit a second-line therapy. Intravenous cidofovir is similarlyeffective,<xref ref-type="bibr" rid="ref57">57</xref>,<xref ref-type="bibr" rid="ref58">58</xref> has become unpopular due to a highrisk of substantial renal injury and uveitis/hypotony.<xref ref-type="bibr" rid="ref59">59</xref> Local therapywith ganciclovir implants is the most effective anti-CMVtreatment option in terms of time-to-retinitis relapse, and is stillused in wealthy countries for immediately vision-threateningdisease,<xref ref-type="bibr" rid="ref47">47</xref>,<xref ref-type="bibr" rid="ref49">49</xref>,<xref ref-type="bibr" rid="ref60">60</xref>,<xref ref-type="bibr" rid="ref61">61</xref> generally in combination with valganciclovirto prevent systemic complications (see above). However,because of the need to treat with valganciclovir anyway, mostuse valganciclovir monotherapy to treat lesions that are notimmediately vision-threatening, particularly if there is hope forimmune recovery. Intravitreal injections of fomivirsen<xref ref-type="bibr" rid="ref62">62</xref>,<xref ref-type="bibr" rid="ref63">63</xref> are no longer marketed because demand for the product was poor.</p><p>As the cost of all of these regimens is exceptionally high,on an order substantially higher than first-line HAART, noneof them are commonly used except in wealthy countries. Themost common approach to treating CMV retinitis in a largepart of the world is to use intravitreal injections of ganciclovir(2.0 to &#x02212;5.0 mg/0.1 cc twice weekly for three weeks, thenweekly) or occasionally foscarnet (2.4 mg/0.1 cc twice weeklyfor three weeks, then weekly). This approach, although ithas not been subjected to randomized trials, seems effectivebased on case series<xref ref-type="bibr" rid="ref64">64</xref>-<xref ref-type="bibr" rid="ref67">67</xref> and clinical experience,but may be associated with a higher risk of second eye and systemic diseasesequelae of CMV disease than a systemic treatment would be.Valganciclovir, which will not be available in generic formuntil 2014, may represent an improvement, particularly vis-&#x000e0;-vis systemic and second eye disease outcomes, but its cost-effectiveness as a generic drug vis-&#x000e0;-vis intravitreal injectionsremains to be seen.</p><p>With the anticipated widespread uptake of co-trimoxazoleprophylaxis and absent full-scale implementation of HAART inmost parts of the world, the number of cases of CMV retinitis,which may be already in the millions, is likely to nearly double.This substantial and increasing burden of disease calls for amore effective yet practical management strategy for CMVretinitis that can be implemented in resource-constrainedsettings. Ophthalmologists worldwide should be familiar withthe diagnosis and management of CMV retinitis, and shouldestablish partnerships with infectious diseases&#x02032; physiciansable to provide appropriate treatment for patients with ocularcomplications of HIV/AIDS, because antiretroviral therapy isultimately the most effective long-term treatment for CMVretinitis and for other ocular complications of AIDS. Researchis needed to determine the optimal way of managing CMVretinitis in resource-constrained settings, particularly in thewindow before HAART-induced immune recovery occurs,during which the risk of vision loss and other complicationsis substantial.</p></body><back><fn-group><fn><p>Source of Support: The Paul and Evanina Mackall Foundation</p></fn><fn><p>Conflict of Interest: None declared</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><collab>Centers for Disease Control</collab><article-title>Pneumocystis pneumonia-LosAngeles</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>1981</year><volume>30</volume><fpage>250</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">6265753</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>J</given-names></name></person-group><article-title>HIV-AIDS. India slashes estimate of HIV-infected people</article-title><source>Science</source><year>2007</year><volume>317</volume><fpage>179</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">17626851</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="webpage"><source>UNAIDS Annual Report 2007: Know Your Epidemic. UNAIDS, Geneva, Switzerland.</source><date-in-citation>accessed July 17, 2008</date-in-citation><comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://data.unaids.org/pub/Report/2008/jc1535_annual_report07_en.pdf">http://data.unaids.org/pub/Report/2008/jc1535_annual_report07_en.pdf</ext-link></comment></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="gov"><article-title>United Nations Development Programme</article-title><source>Human Development Report 2005. </source><year>2005</year></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischl</surname><given-names>MA</given-names></name><name><surname>Dickinson</surname><given-names>GM</given-names></name><name><surname>La Voie</surname><given-names>L</given-names></name></person-group><article-title>Safety and efficacy ofsulfamethoxazole and trimethoprim chemoprophylaxis for<italic>Pneumocystis carinii</italic> pneumonia in AIDS</article-title><source>JAMA</source><year>1988</year><volume>259</volume><fpage>1185</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">3257532</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierce</surname><given-names>M</given-names></name><name><surname>Crampton</surname><given-names>S</given-names></name><name><surname>Henry</surname><given-names>D</given-names></name><name><surname>Heifets</surname><given-names>L</given-names></name><name><surname>LaMarca</surname><given-names>A</given-names></name><name><surname>Montecalvo</surname><given-names>M</given-names></name><etal/></person-group><article-title>A randomized trial of clarithromycin asprophylaxis against disseminated <italic>Mycobacterium avium</italic> complexinfection in patients with advanced acquired immunodeficiencysyndrome</article-title><source>N Engl J Med</source><year>1996</year><volume>335</volume><fpage>384</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">8663871</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitahata</surname><given-names>MM</given-names></name><name><surname>Koepsell</surname><given-names>TD</given-names></name><name><surname>Deyo</surname><given-names>RA</given-names></name><name><surname>Maxwell</surname><given-names>CL</given-names></name><name><surname>Dodge</surname><given-names>WT</given-names></name><name><surname>Wagner</surname><given-names>EH</given-names></name></person-group><article-title>Physicians&#x02032; experience with the acquiredimmunodeficiency syndrome as a factor in patients&#x02032; survival</article-title><source>N Engl J Med</source><year>1996</year><volume>334</volume><fpage>701</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8594430</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoover</surname><given-names>DR</given-names></name><name><surname>Saah</surname><given-names>AJ</given-names></name><name><surname>Bacellar</surname><given-names>H</given-names></name><name><surname>Phair</surname><given-names>J</given-names></name><name><surname>Detels</surname><given-names>R</given-names></name><name><surname>Anderson</surname><given-names>R</given-names></name><etal/></person-group><article-title>Clinical manifestations of AIDS in the era of pneumocystisprophylaxis: Multicenter AIDS Cohort Study</article-title><source>N Engl J Med</source><year>1993</year><volume>329</volume><fpage>1922</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7902536</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="gov"><collab>World Health Organization</collab><article-title>Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents andadults</article-title><source>Recommendations for a public health approach</source><year>2006</year><fpage>1</fpage><lpage>66</lpage></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bartlett</surname><given-names>JG</given-names></name><name><surname>Gallant</surname><given-names>JE</given-names></name></person-group><source>Medical management of HIV infection</source><year>2000</year></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukashov</surname><given-names>VV</given-names></name><name><surname>Goudsmit</surname><given-names>J</given-names></name></person-group><article-title>HIV heterogeneity and disease progression in AIDS: A model of continuous virus adaptation</article-title><source>AIDS</source><year>1998</year><volume>12</volume><fpage>S43</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">9632983</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coffin</surname><given-names>JM</given-names></name></person-group><article-title>HIV population dynamics in vivo : Implications for geneticvariation, pathogenesis and therapy</article-title><source>Science</source><year>1995</year><volume>267</volume><fpage>483</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7824947</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parienti</surname><given-names>JJ</given-names></name><name><surname>Massari</surname><given-names>V</given-names></name><name><surname>Descamps</surname><given-names>D</given-names></name><name><surname>Vabret</surname><given-names>A</given-names></name><name><surname>Bouvet</surname><given-names>E</given-names></name><name><surname>Larouze</surname><given-names>B</given-names></name><etal/></person-group><article-title>Predictors of virologic failure and resistance in HIV-infectedpatients treated with nevirapine- or efavirenz-based antiretroviraltherapy</article-title><source>Clin Infect Dis</source><year>2004</year><volume>38</volume><fpage>1311</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15127346</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ickovics</surname><given-names>JR</given-names></name><name><surname>Cameron</surname><given-names>A</given-names></name><name><surname>Zackin</surname><given-names>R</given-names></name><name><surname>Bassett</surname><given-names>R</given-names></name><name><surname>Chesney</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>VA</given-names></name><etal/></person-group><article-title>Consequences and determinants of adherence toantiretroviral medication: Results from Adult AIDS Clinical TrialsGroup protocol 370</article-title><source>Antivir Ther</source><year>2002</year><volume>7</volume><fpage>185</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">12487386</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischl</surname><given-names>MA</given-names></name><name><surname>Richman</surname><given-names>DD</given-names></name><name><surname>Grieco</surname><given-names>MH</given-names></name><name><surname>Gottlieb</surname><given-names>MS</given-names></name><name><surname>Volberding</surname><given-names>PA</given-names></name><name><surname>Laskin</surname><given-names>OL</given-names></name><etal/></person-group><article-title>The efficacy of azidothymidine (AZT) in thetreatment of patients with AIDS and AIDS-related complex:A double-blind, placebo-controlled trial</article-title><source>N Engl J Med</source><year>1987</year><volume>317</volume><fpage>185</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">3299089</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deeks</surname><given-names>SG</given-names></name><name><surname>Smith</surname><given-names>M</given-names></name><name><surname>Holodniy</surname><given-names>M</given-names></name><name><surname>Kahn</surname><given-names>JO</given-names></name></person-group><article-title>HIV-1 proteaseinhibitors: A review for clinicians</article-title><source>JAMA</source><year>1997</year><volume>277</volume><fpage>145</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">8990341</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flexner</surname><given-names>C</given-names></name></person-group><article-title>HIV-protease inhibitors</article-title><source>N Engl J Med</source><year>1998</year><volume>338</volume><fpage>1281</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">9562584</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moyle</surname><given-names>GJ</given-names></name><name><surname>Sabin</surname><given-names>CA</given-names></name><name><surname>Cartledge</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>Wilkins</surname><given-names>E</given-names></name><name><surname>Churchill</surname><given-names>D</given-names></name><etal/></person-group><article-title>A randomized comparative trial of tenofovir DF or abacavir asreplacement for a thymidine analogue in persons with lipoatrophy</article-title><source>AIDS</source><year>2006</year><volume>20</volume><fpage>2043</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">17053350</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamjian</surname><given-names>MC</given-names></name><name><surname>McNicholl</surname><given-names>IR</given-names></name></person-group><article-title>Enfuvirtide: First fusion inhibitorfor treatment of HIV infection</article-title><source>Am J Health Syst Pharm</source><year>2004</year><volume>61</volume><fpage>1242</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15259753</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krentz</surname><given-names>HB</given-names></name><name><surname>Kliewer</surname><given-names>G</given-names></name><name><surname>Gill</surname><given-names>MJ</given-names></name></person-group><article-title>Changing mortality rates and causesof death for HIV-infected individuals living in Southern Alberta,Canada from 1984 to 2003</article-title><source>HIV Med</source><year>2005</year><volume>6</volume><fpage>99</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">15807715</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palella</surname><given-names>FJ</given-names><suffix>Jr</suffix></name><name><surname>Delaney</surname><given-names>KM</given-names></name><name><surname>Moorman</surname><given-names>AC</given-names></name><name><surname>Loveless</surname><given-names>MO</given-names></name><name><surname>Fuhrer</surname><given-names>J</given-names></name><name><surname>Satten</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Declining morbidity and mortality among patientswith advanced human immunodeficiency virus infection</article-title><source>N Engl J Med</source><year>1998</year><volume>338</volume><fpage>853</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">9516219</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieuwkerk</surname><given-names>PT</given-names></name><name><surname>Reijers</surname><given-names>MH</given-names></name><name><surname>Weigel</surname><given-names>HM</given-names></name><name><surname>Lange</surname><given-names>JM</given-names></name><name><surname>Sprangers</surname><given-names>MA</given-names></name></person-group><article-title>Quality of life in maintenance vs prolonged induction therapy forHIV</article-title><source>JAMA</source><year>2000</year><volume>284</volume><fpage>178</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10889587</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabs</surname><given-names>DA</given-names></name><name><surname>Bartlett</surname><given-names>JG</given-names></name></person-group><article-title>AIDS and ophthalmology: A period oftransition</article-title><source>Am J Ophthalmol</source><year>1997</year><volume>124</volume><fpage>227</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">9262548</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempen</surname><given-names>JH</given-names></name><name><surname>Jabs</surname><given-names>DA</given-names></name><name><surname>Wilson</surname><given-names>LA</given-names></name><name><surname>Dunn</surname><given-names>JP</given-names></name><name><surname>West</surname><given-names>SK</given-names></name><name><surname>Tonascia</surname><given-names>J</given-names></name></person-group><article-title>Mortality risk for patients with cytomegalovirus retinitisand acquired immune deficiency syndrome</article-title><source>Clin Infect Dis</source><year>2003</year><volume>37</volume><fpage>1365</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">14583871</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempen</surname><given-names>JH</given-names></name><name><surname>Jabs</surname><given-names>DA</given-names></name><name><surname>Wilson</surname><given-names>LA</given-names></name><name><surname>Dunn</surname><given-names>JP</given-names></name><name><surname>West</surname><given-names>SK</given-names></name></person-group><article-title>Incidence ofcytomegalovirus (CMV) retinitis in second eyes of patients withthe acquired immune deficiency syndrome and unilateral CMVretinitis</article-title><source>Am J Ophthalmol</source><year>2005</year><volume>139</volume><fpage>1028</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">15953432</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempen</surname><given-names>JH</given-names></name><name><surname>Jabs</surname><given-names>DA</given-names></name><name><surname>Dunn</surname><given-names>JP</given-names></name><name><surname>West</surname><given-names>SK</given-names></name><name><surname>Tonascia</surname><given-names>J</given-names></name></person-group><article-title>Retinaldetachment risk in cytomegalovirus retinitis related to the acquiredimmunodeficiency syndrome</article-title><source>Arch Ophthalmol</source><year>2001</year><volume>119</volume><fpage>33</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">11146724</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempen</surname><given-names>JH</given-names></name><name><surname>Jabs</surname><given-names>DA</given-names></name><name><surname>Wilson</surname><given-names>LA</given-names></name><name><surname>Dunn</surname><given-names>JP</given-names></name><name><surname>West</surname><given-names>SK</given-names></name><name><surname>Tonascia</surname><given-names>JA</given-names></name></person-group><article-title>Risk of vision loss in patients with cytomegalovirus retinitis andthe acquired immunodeficiency syndrome</article-title><source>Arch Ophthalmol</source><year>2003</year><volume>121</volume><fpage>466</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">12695243</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masur</surname><given-names>H</given-names></name><name><surname>Kaplan</surname><given-names>JE</given-names></name><name><surname>Holmes</surname><given-names>KK</given-names></name></person-group><article-title>Guidelines for preventingopportunistic infections among HIV-infected persons-2002.Recommendations of the U.S. Public Health Service andthe Infectious Diseases Society of America</article-title><source>Ann Intern Med</source><year>2002</year><volume>137</volume><fpage>435</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">12617574</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabs</surname><given-names>DA</given-names></name><name><surname>Van Natta</surname><given-names>ML</given-names></name><name><surname>Kempen</surname><given-names>JH</given-names></name><name><surname>Reed Pavan</surname><given-names>P</given-names></name><name><surname>Lim</surname><given-names>JI</given-names></name><name><surname>Murphy</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Characteristics of patients with cytomegalovirusretinitis in the era of highly active antiretroviral therapy</article-title><source>Am J Ophthalmol</source><year>2002</year><volume>133</volume><fpage>48</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">11755839</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempen</surname><given-names>JH</given-names></name><name><surname>Min</surname><given-names>YI</given-names></name><name><surname>Freeman</surname><given-names>WR</given-names></name><name><surname>Holland</surname><given-names>GN</given-names></name><name><surname>Friedberg</surname><given-names>DN</given-names></name><name><surname>Dieterich</surname><given-names>DT</given-names></name><etal/></person-group><article-title>Risk of immune recovery uveitis in patientswith AIDS and cytomegalovirus retinitis</article-title><source>Ophthalmology</source><year>2006</year><volume>113</volume><fpage>684</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">16581429</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinbrook</surname><given-names>R</given-names></name></person-group><article-title>HIV in India-the challenges ahead</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><fpage>1197</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">17377154</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabs</surname><given-names>DA</given-names></name></person-group><article-title>Ocular manifestations of HIV infection</article-title><source>Trans Am Ophthalmol Soc</source><year>1995</year><volume>93</volume><fpage>623</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">8719695</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoover</surname><given-names>DR</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Saah</surname><given-names>A</given-names></name><name><surname>Semba</surname><given-names>R</given-names></name><name><surname>Detels</surname><given-names>RR</given-names></name><name><surname>Rinaldo</surname><given-names>CR</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Occurrence of cytomegalovirus retinitis after humanimmunodeficiency virus immunosuppression</article-title><source>Arch Ophthalmol</source><year>1996</year><volume>114</volume><fpage>821</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8660165</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumarasamy</surname><given-names>N</given-names></name><name><surname>Vallabhaneni</surname><given-names>S</given-names></name><name><surname>Flanigan</surname><given-names>TP</given-names></name><name><surname>Mayer</surname><given-names>KH</given-names></name><name><surname>Solomon</surname><given-names>S</given-names></name></person-group><article-title>Clinical profile of HIV in India</article-title><source>Indian J Med Res</source><year>2005</year><volume>121</volume><fpage>377</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">15817951</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>J</given-names></name><name><surname>Madhavan</surname><given-names>HN</given-names></name><name><surname>George</surname><given-names>AE</given-names></name><name><surname>Kumarasamy</surname><given-names>N</given-names></name><name><surname>Solomon</surname><given-names>S</given-names></name></person-group><article-title>Ocular lesions associated with HIV infection in India: A seriesof 100 consecutive patients evaluated at a referral center</article-title><source>Am J Ophthalmol</source><year>2000</year><volume>129</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">10653406</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jabs</surname><given-names>DA</given-names></name></person-group><source>Ocular manifestations of AIDS</source><year>1998</year><fpage>123</fpage><lpage>36</lpage></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>SA</given-names></name><name><surname>Heng</surname><given-names>WJ</given-names></name><name><surname>Lim</surname><given-names>TH</given-names></name><name><surname>Leo</surname><given-names>YS</given-names></name><name><surname>Wong</surname><given-names>SY</given-names></name></person-group><article-title>Ophthalmicmanifestations in human immunodeficiency virus infection inSingapore</article-title><source>Ann Acad Med Singapore</source><year>1997</year><volume>26</volume><fpage>575</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">9494660</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mesaric</surname><given-names>B</given-names></name><name><surname>Begovac</surname><given-names>J</given-names></name><name><surname>Ugrinovic</surname><given-names>N</given-names></name><name><surname>Babic</surname><given-names>K</given-names></name><name><surname>Lisic</surname><given-names>M</given-names></name></person-group><article-title>Cytomegalovirusretinitis in patients with human immunodeficiency virus infection</article-title><source>Lijec Vjesn</source><year>1998</year><volume>120</volume><fpage>106</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">9748786</pub-id></element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muccioli</surname><given-names>C</given-names></name><name><surname>Belfort</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Lottenberg</surname><given-names>C</given-names></name><name><surname>Lima</surname><given-names>J</given-names></name><name><surname>Santos</surname><given-names>P</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><etal/></person-group><article-title>Ophthalmological manifestations in AIDS: Evaluation of 445patients in one year</article-title><source>Rev Assoc Med Bras</source><year>1994</year><volume>40</volume><fpage>155</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">7787865</pub-id></element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagata</surname><given-names>Y</given-names></name><name><surname>Fujino</surname><given-names>Y</given-names></name><name><surname>Matsumoto</surname><given-names>S</given-names></name><name><surname>Nishi</surname><given-names>M</given-names></name><name><surname>Ono</surname><given-names>A</given-names></name><name><surname>Mochizuki</surname><given-names>M</given-names></name><etal/></person-group><article-title>Ocular manifestations in Japanese patients with humanimmunodeficiency virus infection</article-title><source>Jpn J Ophthalmol</source><year>1993</year><volume>37</volume><fpage>275</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">8295365</pub-id></element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanterdtam</surname><given-names>J</given-names></name><name><surname>Suwannagool</surname><given-names>S</given-names></name><name><surname>Namatra</surname><given-names>C</given-names></name><name><surname>Singalavanija</surname><given-names>A</given-names></name></person-group><article-title>A study of ocular manifestations in HIV patients</article-title><source>Thai J Ophthalmol</source><year>2002</year><volume>10</volume><fpage>11</fpage><lpage>20</lpage></element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>KH</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Lo</surname><given-names>YC</given-names></name><name><surname>Li</surname><given-names>PC</given-names></name><name><surname>Ho</surname><given-names>HF</given-names></name><name><surname>Sitt</surname><given-names>WH</given-names></name><etal/></person-group><article-title>Profile ofopportunistic infections among HIV-1 infected people in Hong Kong</article-title><source>Zhonghua Yi Xue Za Zhi (Taipei)</source><year>1995</year><volume>55</volume><fpage>127</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">7750052</pub-id></element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kestelyn</surname><given-names>P</given-names></name></person-group><article-title>The epidemiology of CMV retinitis in Africa</article-title><source>Ocul Immunol Inflamm</source><year>1999</year><volume>7</volume><fpage>173</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10611725</pub-id></element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kempen</surname><given-names>JH</given-names></name><name><surname>Jabs</surname><given-names>DA</given-names></name></person-group><source>Ocular complications of HIV infection</source><year>2003</year><edition>2nd ed</edition><fpage>318</fpage><lpage>40</lpage></element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arevalo</surname><given-names>JF</given-names></name><name><surname>Gonzalez</surname><given-names>C</given-names></name><name><surname>Capparelli</surname><given-names>EV</given-names></name><name><surname>Kirsch</surname><given-names>LS</given-names></name><name><surname>Garcia</surname><given-names>RF</given-names></name><name><surname>Quiceno</surname><given-names>JI</given-names></name><etal/></person-group><article-title>Intravitreous and plasma concentrations ofganciclovir and foscarnet after intravenous therapy in patients withAIDS and cytomegalovirus retinitis</article-title><source>J Infect Dis</source><year>1995</year><volume>172</volume><fpage>951</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7561215</pub-id></element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabs</surname><given-names>DA</given-names></name><name><surname>Enger</surname><given-names>C</given-names></name><name><surname>Dunn</surname><given-names>JP</given-names></name><name><surname>Forman</surname><given-names>M</given-names></name></person-group><collab>CMV Retinitis and ViralResistance Study Group</collab><article-title>Cytomegalovirus retinitis and viralresistance: Ganciclovir resistance</article-title><source>J Infect Dis</source><year>1998</year><volume>177</volume><fpage>770</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">9498461</pub-id></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musch</surname><given-names>DC</given-names></name><name><surname>Martin</surname><given-names>DF</given-names></name><name><surname>Gordon</surname><given-names>JF</given-names></name><name><surname>Davis</surname><given-names>MD</given-names></name><name><surname>Kuppermann</surname><given-names>BD</given-names></name></person-group><article-title>Treatment of cytomegalovirus retinitis with a sustained-releaseganciclovir implant: The Ganciclovir Implant Study Group</article-title><source>N Engl J Med</source><year>1997</year><volume>337</volume><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">9211677</pub-id></element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binquet</surname><given-names>C</given-names></name><name><surname>Saillour</surname><given-names>F</given-names></name><name><surname>Bernard</surname><given-names>N</given-names></name><name><surname>Rougier</surname><given-names>MB</given-names></name><name><surname>Leger</surname><given-names>F</given-names></name><name><surname>Bonnal</surname><given-names>F</given-names></name><etal/></person-group><article-title>Prognostic factors of survival of HIV-infected patients withcytomegalovirus disease: Aquitaine Cohort, 1986-1997</article-title><source>Eur J Epidemiol</source><year>2000</year><volume>16</volume><fpage>425</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">10997829</pub-id></element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>DF</given-names></name><name><surname>Kuppermann</surname><given-names>BD</given-names></name><name><surname>Wolitz</surname><given-names>RA</given-names></name><name><surname>Palestine</surname><given-names>AG</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Robinson</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Oral ganciclovir for patients withcytomegalovirus retinitis treated with a ganciclovir implant</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><fpage>1063</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">10194235</pub-id></element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skiest</surname><given-names>DJ</given-names></name><name><surname>Chiller</surname><given-names>T</given-names></name><name><surname>Chiller</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>A</given-names></name><name><surname>Keiser</surname><given-names>P</given-names></name></person-group><article-title>Protease inhibitortherapy is associated with markedly prolonged time to relapse andimproved survival in AIDS patients with cytomegalovirus retinitis</article-title><source>Int J STD AIDS</source><year>2001</year><volume>12</volume><fpage>659</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">11564333</pub-id></element-citation></ref><ref id="ref51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>DF</given-names></name><name><surname>Sierra-Madero</surname><given-names>J</given-names></name><name><surname>Walmsley</surname><given-names>S</given-names></name><name><surname>Wolitz</surname><given-names>RA</given-names></name><name><surname>Macey</surname><given-names>K</given-names></name><name><surname>Georgiou</surname><given-names>P</given-names></name><etal/></person-group><article-title>A controlled trial of valganciclovir as inductiontherapy for cytomegalovirus retinitis</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><fpage>1119</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">11948271</pub-id></element-citation></ref><ref id="ref52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorne</surname><given-names>JE</given-names></name><name><surname>Jabs</surname><given-names>DA</given-names></name><name><surname>Vitale</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>T</given-names></name><name><surname>Dunn</surname><given-names>JP</given-names></name><name><surname>Semba</surname><given-names>RD</given-names></name></person-group><article-title>Cathetercomplications in AIDS patients treated for cytomegalovirusretinitis</article-title><source>AIDS</source><year>1998</year><volume>12</volume><fpage>2321</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9863875</pub-id></element-citation></ref><ref id="ref53"><label>53</label><element-citation publication-type="journal"><collab>Collaborative DHPG Treatment Study Group</collab><article-title>Treatment ofserious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and otherimmunodeficiencies</article-title><source>N Engl J Med</source><year>1986</year><volume>314</volume><fpage>801</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">3005861</pub-id></element-citation></ref><ref id="ref54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spector</surname><given-names>SA</given-names></name><name><surname>Weingeist</surname><given-names>T</given-names></name><name><surname>Pollard</surname><given-names>RB</given-names></name><name><surname>Dieterich</surname><given-names>DT</given-names></name><name><surname>Samo</surname><given-names>T</given-names></name><name><surname>Benson</surname><given-names>CA</given-names></name><etal/></person-group><article-title>A randomized, controlled study of intravenousganciclovir therapy for cytomegalovirus peripheral retinitis inpatients with AIDS</article-title><source>J Infect Dis</source><year>1993</year><volume>168</volume><fpage>557</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">8394858</pub-id></element-citation></ref><ref id="ref55"><label>55</label><element-citation publication-type="journal"><collab>Studies of Ocular Complications of AIDS Research Group incollaboration with the AIDS Clinical Trials Group</collab><article-title>Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial 4: Visual outcomes</article-title><source>Ophthalmology</source><year>1994</year><volume>101</volume><fpage>1250</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">8035989</pub-id></element-citation></ref><ref id="ref56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palestine</surname><given-names>AG</given-names></name><name><surname>Polis</surname><given-names>MA</given-names></name><name><surname>De</surname><given-names>S</given-names></name><name><surname>Baird</surname><given-names>BF</given-names></name><name><surname>Falloon</surname><given-names>J</given-names></name><name><surname>Kovacs</surname><given-names>JA</given-names></name><etal/></person-group><article-title>A randomized, controlled trial of foscarnet in the treatment ofcytomegalovirus retinitis in patients with AIDS</article-title><source>Ann Intern Med</source><year>1991</year><volume>115</volume><fpage>665</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">1656826</pub-id></element-citation></ref><ref id="ref57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lalezari</surname><given-names>JP</given-names></name><name><surname>Stagg</surname><given-names>RJ</given-names></name><name><surname>Kuppermann</surname><given-names>BD</given-names></name><name><surname>Holland</surname><given-names>GN</given-names></name><name><surname>Kramer</surname><given-names>F</given-names></name><name><surname>Ives</surname><given-names>DV</given-names></name><etal/></person-group><article-title>Intravenous cidofovir for peripheral cytomegalovirusretinitis in patients with AIDS: A randomized, controlled trial</article-title><source>Ann Intern Med</source><year>1997</year><volume>126</volume><fpage>257</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">9036797</pub-id></element-citation></ref><ref id="ref58"><label>58</label><element-citation publication-type="journal"><collab>Studies of Ocular Complications of AIDS Research Group incollaboration with the AIDS Clinical Trials Group</collab><article-title>Parenteralcidofovir for cytomegalovirus retinitis in patients with AIDS: TheHPMPC peripheral cytomegalovirus retinitis trial: A randomized,controlled trial</article-title><source>Ann Intern Med</source><year>1997</year><volume>126</volume><fpage>264</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">9036798</pub-id></element-citation></ref><ref id="ref59"><label>59</label><element-citation publication-type="journal"><collab>Studies of Ocular Complications of AIDS Research Group incollaboration with the AIDS Clinical Trials Group</collab><article-title>Long-term follow-up of patients with AIDS treated with parenteralcidofovir for cytomegalovirus retinitis: The HPMPC PeripheralCytomegalovirus Retinitis Trial</article-title><source>AIDS</source><year>2000</year><volume>14</volume><fpage>1571</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">10983644</pub-id></element-citation></ref><ref id="ref60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>DF</given-names></name><name><surname>Parks</surname><given-names>DJ</given-names></name><name><surname>Mellow</surname><given-names>SD</given-names></name><name><surname>Ferris</surname><given-names>FL</given-names></name><name><surname>Walton</surname><given-names>RC</given-names></name><name><surname>Remaley</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Treatment of cytomegalovirus retinitis with anintraocular sustained-release ganciclovir implant: A randomizedcontrolled clinical trial</article-title><source>Arch Ophthalmol</source><year>1994</year><volume>112</volume><fpage>1531</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">7993207</pub-id></element-citation></ref><ref id="ref61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>DF</given-names></name><name><surname>Dunn</surname><given-names>JP</given-names></name><name><surname>Davis</surname><given-names>JL</given-names></name><name><surname>Duker</surname><given-names>JS</given-names></name><name><surname>Engstrom</surname><given-names>RE</given-names><suffix>Jr</suffix></name><name><surname>Friedberg</surname><given-names>DN</given-names></name><etal/></person-group><article-title>Use of the ganciclovir implant for the treatmentof cytomegalovirus retinitis in the era of potent antiretroviraltherapy: Recommendations of the International AIDS Society-USA panel</article-title><source>Am J Ophthalmol</source><year>1999</year><volume>127</volume><fpage>329</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">10088745</pub-id></element-citation></ref><ref id="ref62"><label>62</label><element-citation publication-type="journal"><collab>Vitravene Study Group</collab><article-title>A randomized controlled clinical trialof intravitreous fomivirsen for treatment of newly diagnosedperipheral cytomegalovirus retinitis in patients with AIDS</article-title><source>Am J Ophthalmol</source><year>2002</year><volume>133</volume><fpage>467</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">11931780</pub-id></element-citation></ref><ref id="ref63"><label>63</label><element-citation publication-type="journal"><collab>Vitravene Study Group</collab><article-title>Randomized dose-comparison studies ofintravitreous fomivirsen for treatment of cytomegalovirus retinitisthat has reactivated or is persistently active despite other therapiesin patients with AIDS</article-title><source>Am J Ophthalmol</source><year>2002</year><volume>133</volume><fpage>475</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">11931781</pub-id></element-citation></ref><ref id="ref64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baudouin</surname><given-names>C</given-names></name><name><surname>Chassain</surname><given-names>C</given-names></name><name><surname>Caujolle</surname><given-names>C</given-names></name><name><surname>Gastaud</surname><given-names>P</given-names></name></person-group><article-title>Treatment ofcytomegalovirus retinitis in AIDS patients using intravitrealinjections of highly concentrated ganciclovir</article-title><source>Ophthalmologica</source><year>1996</year><volume>210</volume><fpage>329</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">8887389</pub-id></element-citation></ref><ref id="ref65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cochereau-Massin</surname><given-names>I</given-names></name><name><surname>LeHoang</surname><given-names>P</given-names></name><name><surname>Lautier-Frau</surname><given-names>M</given-names></name><name><surname>Zazoun</surname><given-names>L</given-names></name><name><surname>Marcel</surname><given-names>P</given-names></name><name><surname>Robinet</surname><given-names>M</given-names></name><etal/></person-group><article-title>Efficacy and tolerance of intravitrealganciclovir in cytomegalovirus retinitis in acquired immunedeficiency syndrome</article-title><source>Ophthalmology</source><year>1991</year><volume>98</volume><fpage>1348</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">1658703</pub-id></element-citation></ref><ref id="ref66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>S</given-names></name><name><surname>Morlet</surname><given-names>N</given-names></name><name><surname>Besen</surname><given-names>G</given-names></name><name><surname>Wiley</surname><given-names>CA</given-names></name><name><surname>Jones</surname><given-names>P</given-names></name><name><surname>Gold</surname><given-names>J</given-names></name><etal/></person-group><article-title>High-dose (2000-microgram) intravitreous ganciclovir in the treatmentof cytomegalovirus retinitis</article-title><source>Ophthalmology</source><year>1998</year><volume>105</volume><fpage>1404</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">9709750</pub-id></element-citation></ref><ref id="ref67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz-Llopis</surname><given-names>M</given-names></name><name><surname>Espana</surname><given-names>E</given-names></name><name><surname>Munoz</surname><given-names>G</given-names></name><name><surname>Navea</surname><given-names>A</given-names></name><name><surname>Chipont</surname><given-names>E</given-names></name><name><surname>Cano</surname><given-names>J</given-names></name><etal/></person-group><article-title>High dose intravitreal foscarnet in the treatment ofcytomegalovirus retinitis in AIDS</article-title><source>Br J Ophthalmol</source><year>1994</year><volume>78</volume><fpage>120</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">8123619</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><p>HIV prevalence in India-By district, 2005Source: NACO. Sentinel Surveillance data, ANC sites (2005). Reproduced with kind permission from UN AIDS (2006)</p></caption><alt-text>Figure 1</alt-text><graphic xlink:href="IndianJOphthalmol-56-385-g001"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Antiretroviral agents approved by the United States Food and Drug Administration*</p></caption><alt-text>Table 1</alt-text><graphic xlink:href="IndianJOphthalmol-56-385-g002"/></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Ocular complications of human immunodeficiency virus infection: Relationship to degree of immunodeficiency*</p></caption><alt-text>Table 2</alt-text><graphic xlink:href="IndianJOphthalmol-56-385-g003"/></table-wrap></floats-group></article>